acitretin has been researched along with Obesity in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baran, A; Flisiak, I; Kiluk, P; Maciaszek, M; Ĺwiderska, M | 1 |
| Kirby, B; Ryan, C | 1 |
| Arenberger, P; Cetkovska, P; Dolezal, T; Fialova, J; Gkalpakiotis, S; Jircikova, J; Kojanova, M | 1 |
| Beutner, KR; Bhushan, R; Elmets, CA; Feldman, SR; Gordon, KB; Gottlieb, A; Koo, JY; Korman, NJ; Lebwohl, M; Leonardi, CL; Menter, A; Van Voorhees, AS | 1 |
1 review(s) available for acitretin and Obesity
| Article | Year |
|---|---|
Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
Topics: Acitretin; Adipokines; Alcoholism; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Comorbidity; Cyclosporine; Dermatologic Agents; Diabetes Mellitus; Fumarates; Humans; Immunosuppressive Agents; Inflammation; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; Risk Factors; Smoking; Tumor Necrosis Factor-alpha; Ustekinumab | 2015 |
3 other study(ies) available for acitretin and Obesity
| Article | Year |
|---|---|
Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acitretin; Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Female; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Obesity; Psoriasis; Risk Factors; Young Adult | 2020 |
Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
Topics: Acitretin; Adult; Biological Products; Body Mass Index; Comorbidity; Coronary Disease; Cyclosporine; Czech Republic; Dermatologic Agents; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; Keratolytic Agents; Male; Methotrexate; Middle Aged; Obesity; Phototherapy; Prevalence; Psoriasis; Quality of Life; Registries; Retreatment; Retrospective Studies; Risk Factors; Severity of Illness Index | 2017 |
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Topics: Acitretin; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cyclosporine; Depression; Etanercept; Humans; Immunoglobulin G; Interleukin-12; Interleukin-23; Lymphoma; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Smoking; Tumor Necrosis Factor-alpha | 2008 |